Skip to main content

Table 1 Inflammation markers during the patient follow up

From: Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome

Date Age Leucocytes ×109/L Neutrophils ×109/L CRP mg/L
June 2015 2 y 10 mo 8.27 7.51 114.09
April 2016 3 y 8 mo 16.62 11.01 23.71
November 2016 4 y 3 mo 16.12 12.16 16.3
January 2017 4 y 5 mo 10.81 9.11 76.18
March 2017 4 y 7 mo 10.89 5.12 43.04
Start of Baricitinib in August 2017
 September 2017 5 y 0 mo 16.88 12.24 2.8
 October 2017 5 y 2 mo 8.73 3.5 0.13
 December 2017 5 y 4 mo 7.66 3.53 8.78
 February 2018 5 y 5 mo 7.89 4.47 17.13
 April 2018 5 y 7 mo 6.74 2.78 7.48
 February 2019 6 y 5 mo 7.5 5.79 18.63